Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Enzyme Appears to Predict RCC Death Risk

J Clin Oncol; 2017 Nov 10; Ho, Kapur, et al

A specific enzyme appears to predict renal cell carcinoma death risk better than existing methods, according to an analysis involving nearly 2,000 individuals. It seems to be particularly accurate in low- and intermediate-risk tumors. Investigators looked at the impact tumor-based enhancer of zeste homolog 2 (EZH2) gene and protein expression had on overall survival in participants from 3 cohorts. Among the results:

  • Patients from the Cancer Genome Atlas with EZH2-high gene expression were 50% more likely to experience overall death than those with low expression.
  • Overall death risk in the University of Texas Southwestern Medical Center cohort was twice as high as those with low expression.
  • It was 40% higher in the Mayo Clinic cohort.
  • Patients in the Mayo group with EZH2-high protein expression were twice as likely to experience RCC-specific death.
  • EZH2 protein expression was particularly prognostic in patients with low-risk tumors.

Citation:

Ho T, Kapur P, Eckel-Passow J, et al. Multicenter validation of enhancer of zeste homolog 2 expression as an independent prognostic marker in localized clear cell renal cell carcinoma. J Clin Oncol. 2017;35(32):3706-3713. doi:10.1200/JCO.2017.73.3238.

This Week's Must Reads

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.

Must Reads in Renal Cell Carcinoma

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.